Lihan is the CEO and Co-Founder of MiRXES, a Singapore-based biotechnology company focused on developing microRNA technologies and innovative molecular diagnostics for cancer and infectious diseases such as COVID-19. Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute in Singapore, A*STAR, where he co-developed a novel microRNA qPCR assay platform and an integrated workflow for biomarker discovery. Lihan has a PhD in Biochemistry from the National University of Singapore. He has authored and co-authored more than 20 peer-reviewed publications and 8 patent applications. Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35.
What is the biggest thing you learned in 2020?
What do you feel are the two most important benefits or areas that need to be a top priority in 2021?
Can you share a story on an area of your healthcare program or employee benefits where you were able to create significant savings or stop costs from rising?
If you could automatically receive a 10-20% reduction in costs in three areas/programs, what would your dream list be?
What is the most innovative program you will focus on in 2021 and/or 2022?
How are you re-imagining corporate culture & well-being?
What virtual care solutions did you roll out during the pandemic? How valuable were they and why?
If you look at our 3 Moonshots - Costs, Culture, and Care; In one sentence, tell us what would be something positive for us to take from 2020 and bring into this new year?